Related Experiment Video

Updated: Jan 18, 2026

Screening Bioactive Nanoparticles in Phagocytic Immune Cells for Inhibitors of Toll-like Receptor Signaling
09:51

Screening Bioactive Nanoparticles in Phagocytic Immune Cells for Inhibitors of Toll-like Receptor Signaling

Published on: July 26, 2017

13.0K

Targeting the Toll-like Receptor Signaling Pathway in Lung Cancer: Therapeutic Opportunities and Challenges

Muhammad Usama1,2, Badar Raza1,2, Mingfei Wu1,2

  • 1Center for Developmental Biology, School of Life Science, Anhui Agricultural University, 230036, Hefei, China.

Current Drug Targets
|September 8, 2025
PubMed

Insights

Toll-Like Receptor (TLR) signaling influences lung cancer progression. Targeting TLRs with agonists or antagonists, alongside immune checkpoint inhibitors, may offer new lung cancer therapies.

Area of Science:

  • Oncology
  • Immunology
  • Molecular Biology

Background:

  • Non-small cell lung cancer (NSCLC) is a major cause of cancer mortality, often diagnosed at advanced stages.
  • The Toll-Like Receptor (TLR) signaling pathway is implicated in inflammation and cancer, exhibiting dual roles in tumor progression.
  • Understanding TLRs' complex functions is vital for developing effective lung cancer treatments.

Purpose of the Study:

  • To explore the multifaceted roles of Toll-Like Receptor (TLR) proteins in lung cancer.
  • To elucidate TLR involvement in tumor growth, angiogenesis, and metastasis.
  • To review the therapeutic potential of TLR agonists and antagonists in lung cancer treatment.

Main Methods:

  • Literature review and synthesis of current research on TLR signaling in lung cancer.
  • Analysis of TLRs' pro-tumor and anti-tumor effects.
  • Examination of therapeutic strategies involving TLRs and immune checkpoint inhibitors.

Main Results:

  • TLR signaling pathways demonstrate complex, context-dependent effects in lung cancer.
  • TLRs influence key cancer hallmarks including tumor growth, angiogenesis, and metastasis.
  • Combinatorial therapies of TLR modulators and immune checkpoint inhibitors show promise.

Conclusions:

  • TLR signaling is a critical mediator in lung cancer development and progression.
  • Targeting TLRs offers potential therapeutic avenues, particularly in combination with immunotherapies.
  • Precise strategies are needed to harness TLRs' dual immune-modulating effects for improved lung cancer outcomes.
Keywords:
TLR agonistsTLR antagonistsToll-like receptorscombination therapy.immune checkpoint inhibitorsimmunotherapylung cancer

More Related Videos

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis11:44

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis

Published on: March 30, 2019

8.0K
Orthotopic Transplantation of Syngeneic Lung Adenocarcinoma Cells to Study PD-L1 Expression06:03

Orthotopic Transplantation of Syngeneic Lung Adenocarcinoma Cells to Study PD-L1 Expression

Published on: January 19, 2019

18.1K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.6K
lncRNA - Long Non-coding RNAs02:39

lncRNA - Long Non-coding RNAs

In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
9.8K
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.8K
Signal Transduction: Overview01:26

Signal Transduction: Overview

Cells respond to many types of information, often through receptor proteins positioned on the membrane. They respond to chemical signals, such as hormones, neurotransmitters, and other signaling molecules, initiating a series of molecular reactions to produce an appropriate response. This is called signal transduction. Cells also coordinate different responses elicited by the same signaling molecule via mediators, allowing molecular cross-talk.
Typically, signal transduction involves three...
11.4K
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
3.9K